MagicMed Industries Inc. is a biotechnology company focused on creating a library of novel derivative molecules based on classic psychedelics such as psilocybin, N,N-dimethyltryptamine (DMT), mescaline, ibogaine, MDMA and LSD.
MagicMed’s molecular derivatives library, the Psybrary™, is intended to be an essential building block from which industry partners can develop new patented products.The Psybrary™
Partners targeting specific indications can survey the derivatives contained in the Psybrary™ and select candidates for focused drug development.
MagicMoments, a new series focused on providing insights into a wide range of topics in the psychedelic, biotechnology and pharmaceutical industries ranging from patents and AI technology to drug development.
Combining PsyAI™ and the Psybrary™, our proprietary library of psychedelic derivatives, creates an opportunity to accelerate the development of optimized pharmaceutical candidates, each potentially tailored specifically for difficult-to-treat mental health indications.
Dr. Joseph Tucker